Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto Psychedelics Investing
Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering Psychedelics Investing
Optimi Health Announces Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression Psychedelics Investing
Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder Psychedelics Investing
SVN-SDN-14 PTSD Programme - Positive pre-clinical results with three high-performing candidates advancing to in vivo studies Biotech Investing
Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA Life Science Investing News
Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights Life Science Investing News
